Neuropeptides and inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 25, Issue 6, 2009, Pages 503-511

  Margolisa, Kara Gross ^a   Gershonb, Michael David ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Inflammatory bowel disease; Neuropeptides; Zintestinal inflammation

Indexed keywords

ACETYLCHOLINE; ASTRESSIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; NEUROPEPTIDE; NEUROTENSIN; SEROTONIN; SUBSTANCE P; UROCORTIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

CLOSTRIDIUM DIFFICILE; CROHN DISEASE; ENTERITIS; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; ULCERATIVE COLITIS;

CENTRAL NERVOUS SYSTEM; COLON; ENTERIC NERVOUS SYSTEM; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; NEUROPEPTIDES; RECEPTORS, NEUROPEPTIDE;

EID: 74549154024     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328331b69e     Document Type: Review

References (159)

1. Linden DR, Couvrette JM, Ciolino A, et al. Indiscriminate loss of myenteric neurones in the TNBS-inflamed guinea-pig distal colon. Neurogastroenterol Motil 2005; 17:751-760.
2. Levite M, Chowers Y. Nerve-driven immunity: neuropeptides regulate cytokine secretion of T cells and intestinal epithelial cells in a direct, powerful and contextual manner. Ann Oncol 2001; 12 (Suppl 2):S19-25.
3. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996; 111:1683-1699.
4. PodolskyDK. Inflammatorybowel disease. N Engl J Med 1991; 325:928-937.
5. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:918-932.
6. Goyal RK, Hirano I. The enteric nervous system. N Engl J Med 1996; 334:1106-1115.
7. Shepherd AJ, Downing JE, Miyan JA. Without nerves, immunology remains incomplete -in vivo veritas. Immunology 2005; 116:145-163.
8. di Mola FF, Friess H, Zhu ZW, et al. Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease. Gut 2000; 46:670-679.
9. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995; 101:428-435.
10. Surrenti C, Renzi D, Garcea MR, et al. Colonic vasoactive intestinal polypeptide in ulcerative colitis. J Physiol Paris 1993; 87:307-311.
11. Bienenstock J, Tomioka M, Matsuda H, et al. The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int Arch Allergy Appl Immunol 1987; 82:238-243.
12. Anton PA. Stress and mind-body impact on the course of inflammatory bowel diseases. Semin Gastrointest Dis 1999; 10:14-19.
13. Dvorak AM, Connell AB, Dickersin GR. Crohn's disease: a scanning electron microscopic study. Hum Pathol 1979; 10:165-177.
14. Vasina V, Barbara G, Talamonti L, et al. Enteric neuroplasticity evoked by inflammation. Auton Neurosci 2006; 126-127:264-272.
15. Davis DR, Dockerty MB, MayoCW. The myenteric plexus in regional enteritis: a study of the number of ganglion cells in the ileum in 24 cases. Surg Gynecol Obstet 1955; 101:208-216.
16. Villanacci V, Bassotti G, Nascimbeni R, et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil 2008; 20:1009-1016.
17. Goode T, O'Connell J, Anton P, et al. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 2000; 47:387-396.
18. Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharmacol Ther 1997; 73:219-263.
19. Liu L, Shang F,Markus I, Burcher E. Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease. J Pharmacol Exp Ther 2002; 302:627-635.
20. Castagliuolo I, Keates AC, Qiu B, et al. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci U S A 1997; 94:4788-4793.
21. Ho WZ, Lai JP, Zhu XH, et al. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997; 159:5654-5660.
22. Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998; 86:80-86.
23. Weinstock JV, Blum A, Walder J, Walder R. Eosinophils from granulomas in murine schistosomiasis mansoni produce substance P. J Immunol 1988; 141:961-966.
24. Gallicchio M, Rosa AC, Benetti E, et al. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. Br J Pharmacol 2006; 147:681-689.
25. Pothoulakis C, Castagliuolo I, Leeman SE, et al. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998; 275 (1 Pt 1):G68-75.
26. Renzi D, Mantellini P, Calabró A, et al. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis. Ital J Gastroenterol Hepatol 1998; 30:62-70.
27. Curtis R. GAP-43 is expressed by nonmyelin-forming Schwann cells of the peripheral nervous system. J Cell Biol 1992; 116:1455-1464.
28. Kimura M, Masuda T, Hiwatashi N, et al. Changes in neuropeptide- containing nerves in human colonic mucosa with inflammatory bowel disease. Pathol Int 1994; 44:624-634.
29. Bernstein CN, Robert ME, Eysselein VE. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993; 88:908-913.
30. Goldin E, Karmeli F, Selinger Z, Rachmilewitz D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci 1989; 34:754-757.
31. Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992; 87: 176-181.
32. Metwali A, Blum AM, Elliott DE, et al. Cutting edge: hemokinin has substance P-like function and expression in inflammation. J Immunol 2004; 172:6528-6532.
33. Vento P, Kiviluto T, Keránen U, et al. Quantitative comparison of growthassociated protein-43 and substance P in ulcerative colitis. J Histochem Cytochem 2001; 49:749-758.
34. Koch TR, Carney JA, Go VL. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 1987; 32:369-376.
35. Michalski CW, Autschbach F, Selvaggi F, et al. Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease. Am J Surg 2007; 193:476-481.
36. Mantyh CR, Gates TS, Zimmerman RP, et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc Natl Acad Sci U S A 1988; 85:3235-3239.
37. Renzi D, Pellegrini B, Tonelli F, et al. Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol 2000; 157:1511-1522.
38. Mantyh CR, Vigna SR, Bollinger RR, et al. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995; 109:850-860.
39. Miampamba M, Sharkey KA. Distribution of calcitonin gene-related peptide, somatostatin, substance P and vasoactive intestinal polypeptide in experimental colitis in rats. Neurogastroenterol Motil 1998; 10:315-329.
40. Niess JH, Mónnikes H, Dignass AU, et al. Review on the influence of stress on immune mediators, neuropeptides and hormones with relevance for inflammatory bowel disease. Digestion 2002; 65:131-140.
41. Sturiale S, Barbara G, Qiu B, et al. Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci U S A 1999; 96:11653-11658.
42. Ursino MG, Vasina V, De Ponti F. Protection from DNBS-induced colitis by the tachykinin NK(1) receptor antagonist SR140333 in rats. Eur J Pharmacol 2009; 603:133-137.
43. Di Sebastiano P, Grossi L, Di Mola FF, et al. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci 1999; 44:439-444.
44. Gad M, Pedersen AE, Kristensen NN, et al. Blockage of the neurokinin 1 receptor and capsaicin-induced ablation of the enteric afferent nerves protect SCID mice against T-cell-induced chronic colitis. Inflamm Bowel Dis 2009.
45. Azzolina A, Bongiovanni A, Lampiasi N. Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochim Biophys Acta 2003; 1643:75-83.
46. Derocq JM, Ségui M, Blazy C, et al. Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists. FEBS Lett 1996; 399:321-325.
47. Fiebich BL, Schleicher S, Butcher RD, et al. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol 2000; 165:5606-5611.
48. Karagiannides I, Kokkotou E, Tansky M, et al. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci U S A 2006; 103:5207-5212.
49. Koon HW, Zhao D, Zhan Y, et al. Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves protein kinase Cdelta activation. J Pharmacol Exp Ther 2005; 314:1393-1400.
50. Lieb K, Fiebich BL, Berger M, et al. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 1997; 159:4952-4958.
51. Zhao D, Kuhnt-Moore S, Zeng H, et al. Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases. Biochem J 2002; 368 (Pt 2):665-672.
52. Castagliuolo I, Morteau O, Keates AC, et al. Protective effects of neurokinin-1 receptor during colitis in mice: role of the epidermal growth factor receptor. Br J Pharmacol 2002; 136:271-279.
53. Apfel CC, Malhotra A, Leslie JB. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting. Curr Opin Anaesthesiol 2008; 21:427-432.
54. Sarcev T, Secen N, Zaric B, Milovancev A. Aprepitant: where do we stand in the control of chemotherapy-induced nausea and vomiting? J BUON 2008; 13:333-339.
55. Mutschler J, Grosshans M, Kiefer F. A new pharmacological treatment option for alcohol dependence discovered in transnational study: neurokinin-1 receptor antagonist as a possible therapy for alcoholism? Neuropsychiatr 2008; 22:283-285.
56. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 2009; 69:515-533.
57. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 2009; 10:629-644.
58. Galy G, Labidi SI, Tissier F, et al. Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study. Bull Cancer 2009; 96:141-145.
59. Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009; 52:242-247.
60. Navari RM. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2008; 8:1733-1742.
61. Lim R, Morrill JM, Prushik SG, et al. An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraabdominal adhesions when administered intraperitoneally, but not orally. J Gastrointest Surg 2008; 12:1754-1761.
62. Vale W, Rivier C, Brown MR, et al. Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res 1983; 39:245-270.
63. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and betaendorphin. Science 1981; 213:1394-1397.
64. Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci 1999; 885:312-328.
65. Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983; 36:165-186.
66. Brown MR, Fisher LA, Spiess J, et al. Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology 1982; 111:928-931.
67. Kawahito Y, Sano H, Mukai S, et al. Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis. Gut 1995; 37:544-551.
68. Lenz HJ, Hester SE, Brown MR. Corticotropin-releasing factor. Mechanisms to inhibit gastric acid secretion in conscious dogs. J Clin Invest 1985; 75:889-895.
69. Million M, Tache Y, Anton P. Susceptibility of Lewis and Fischer rats to stressinduced worsening of TNB-colitis: protective role of brain CRF. Am J Physiol 1999; 276 (4 Pt 1):G1027-G1036.
70. Goetzl EJ, Chan RC, Yadav M. Diverse mechanisms and consequences of immunoadoption of neuromediator systems. Ann N Y Acad Sci 2008; 1144:56-60.
71. Kawahito Y, Sano H, Kawata M, et al. Local secretion of corticotropinreleasing hormone by enterochromaffin cells in human colon. Gastroenterology 1994; 106:859-865.
72. Sutton RE, Koob GF, Le Moal M, et al. Corticotropin releasing factor produces behavioural activation in rats. Nature 1982; 297:331-333.
73. Saruta M, Takahashi K, Suzuki T, et al. Urocortin 1 in colonic mucosa in patients with ulcerative colitis. J Clin Endocrinol Metab 2004; 89:5352-5361.
74. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 2006; 55:824-832.
75. Saito-Nakaya K, Hasegawa R, Nagura Y, et al. Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogastroenterol Motil 2008; 20:1147-1156.
76. Gay J, Kokkotou E, O'Brien M, et al. Corticotropin-releasing hormone deficiency is associated with reduced local inflammation in a mouse model of experimental colitis. Endocrinology 2008; 149:3403-3409.
77. Kokkotou E, Torres D, Moss AC, et al. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 2006; 177:3355-3361.
78. Zhao J, Karalis KP. Regulation of nuclear factor-kappaB by corticotropinreleasing hormone in mouse thymocytes. Mol Endocrinol 2002; 16:2561-2570.
79. Sashinami H, Kageyama K, Suda T, Nakane A. Urocortin 2 suppresses host resistance to Listeria monocytogenes infection via up-regulation of interleukin-10. Endocrinology 2005; 146:5003-5011.
80. Tsatsanis C, Androulidaki A, Dermitzaki E, et al. Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 2005; 579:4259-4264.
81. Carraway R, Leeman SE. The amino acid sequence of a hypothalamic peptide, neurotensin. J Biol Chem 1975; 250:1907-1911.
82. Carraway R, Leeman SE. Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach. J Biol Chem 1976; 251:7045-7052.
83. Holzer P, Bucsics A, Saria A, Lembeck F. A study of the concentrations of substance P and neurotensin in the gastrointestinal tract of various mammals. Neuroscience 1982; 7:2919-2924.
84. Mazella J, Botto JM, Guillemare E, et al. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci 1996; 16:5613-5620.
85. Tanaka K, Masu M, Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 1990; 4:847-854.
86. Brun P, Mastrotto C, Beggiao E, et al. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2005; 288:G621-G629.
87. Zhao D, Keates AC, Kuhnt-Moore S, et al. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 2001; 276:44464-44471.
88. Garrido JJ, Arahuetes RM, Hernanz A, De la Fuente M. Modulation by neurotensin and neuromedin N of adherence and chemotaxis capacity of murine lymphocytes. Regul Pept 1992; 41:27-37.
89. Lemaire I. Neurotensin enhances IL-1 production by activated alveolar macrophages. J Immunol 1988; 140:2983-2988.
90. Selbekk BH, Flaten O, Hanssen LE. The in vitro effect of neurotensin on human jejunal mast cells. Scand J Gastroenterol 1980; 15:457-460.
91. Akcan A, Muhtaroglu S, Akgun H, et al. Ameliorative effects of bombesin and neurotensin on trinitrobenzene sulphonic acid-induced colitis, oxidative damage and apoptosis in rats. World J Gastroenterol 2008; 14:1222-1230.
92. Alexander RJ, Panja A, Kaplan-Liss E, et al. Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. Dig Dis Sci 1995; 40:485-494.
93. Zhao D, Zhan Y, Koon HW, et al. Metalloproteinase-dependent transforming growth factor-alpha release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells. J Biol Chem 2004; 279:43547-43554.
94. Zhao D, Pothoulakis C. Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation. Peptides 2006; 27:2434-2444.
95. Houdeau E, Prudhomme MJ, Rousseau JP. Regional difference in the distribution of vasoactive intestinal polypeptide-immunoreactive nerve fibres along the uterus and between myometrial muscle layers in the rat. Histochem J 1998; 30:525-529.
96. Porter AJ, Wattchow DA, Brookes SJ, Costa M. Projections of nitric oxide synthase and vasoactive intestinal polypeptide-reactive submucosal neurons in the human colon. J Gastroenterol Hepatol 1999; 14:1180-1187.
97. Laburthe M, Couvineau A, Marie JC. VPAC receptors for VIP and PACAP. Receptors Channels 2002; 8:137-153.
98. Newman R, Cuan N, Hampartzoumian T, et al. Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin Exp Immunol 2005; 139:411-420.
99. Schratzberger P,Geiseler A, Dunzendorfer S, et al. Similar involvement of VIP receptor type I and type II in lymphocyte chemotaxis. J Neuroimmunol 1998; 87:73-81.
100. Sirianni MC, Annibale B, Tagliaferri F, et al. Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity. Regul Pept 1992; 38:79-87.
101. Arranz A, Juarranz Y, Leceta J, et al. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 2008; 29:948-956.
102. Arranz A, Androulidaki A, Zacharioudaki V, et al. Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide. Mol Immunol 2008; 45:2970-2980.
103. Delgado M. VIP: a very important peptide in T helper differentiation. Trends Immunol 2003; 24:221-224.
104. Yadav M, Rosenbaum J, Goetzl EJ. Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 2008; 180:2772-2776.
105. Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003; 124:961-971.
106. Bishop AE, Polak JM, Bryant MG, et al. Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease. Gastroenterology 1980; 79 (5 Pt 1):853-860.
107. O'Morain C, Bishop AE, McGregor GP, et al. Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut 1984; 25:57-61.
108. Schneider J, Jehle EC, Starlinger MJ, et al. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in noninflamed rectum of patients with Crohn's disease. Neurogastroenterol Motil 2001; 13:255-264.
109. Neunlist M, Aubert P, Toquet C, et al. Changes in chemical coding of myenteric neurones in ulcerative colitis. Gut 2003; 52:84-90.
110. Jonsson M, Norrgård O, Hansson M, Forsgren S. Decrease in binding for the neuropeptide VIP in response to marked inflammation of the mucosa in ulcerative colitis. Ann N Y Acad Sci 2007; 1107:280-289.
111. Tan YV, Abad C, Lopez R, et al. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2009; 106:2012-2017.
112. Azuma YT, Hagi K, Shintani N, et al. PACAP provides colonic protection against dextran sodium sulfate induced colitis. J Cell Physiol 2008; 216: 111-119.
113. Nemetz N, Abad C, Lawson G, et al. Induction of colitis and rapid development of colorectal tumors in mice deficient in the neuropeptide PACAP. Int J Cancer 2008; 122:1803-1809.
114. Kokkotou E, Espinoza DO, Torres D, et al. Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice. Gut 2009; 58:34-40.
115. Kokkotou E, Moss AC, Torres D, et al. Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A 2008; 105:10613-10618.
116. Bischoff SC, Mailer R, Pabst O, et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am J Physiol Gastrointest Liver Physiol 2009; 296:G685-G695.
117. Linden DR, Foley KF, McQuoid C, et al. Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol Motil 2005; 17:565-574.
118. Linden DR, Chen JX, Gershon MD, et al. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 2003; 285:G207-G216.
119. Kidd M, Gustafsson BI, Drozdov I, Modlin IM. IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease. Neurogastroenterol Motil 2009; 21:439-450.
120. Chandrasekharan B, Bala V, Kolachala VL, et al. Targeted deletion of neuropeptide Y (NPY) modulates experimental colitis. PLoS One 2008; 3:e3304.
121. Anitha M, Chandrasekharan B, Salgado JR, et al. Glial-derived neurotrophic factor modulates enteric neuronal survival and proliferation through neuropeptide Y. Gastroenterology 2006; 131:1164-1178.
122. Gonzalez-Rey E, Varela N, Sheibanie AF, et al. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci U S A 2006; 103:4228-4233.
123. Hosomi S, Oshitani N, Kamata N, et al. Phenotypical and functional study of ghrelin and its receptor in the pathogenesis of Crohn's disease. Inflamm Bowel Dis 2008; 14:1205-1213.
124. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006; 130:1707-1720.
125. Storr MA, Keenan CM, Emmerdinger D, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med 2008; 86:925-936.
126. Assimakopoulos SF, Scopa CD, Nikolopoulou VN, et al. Pleiotropic effects of bombesin and neurotensin on intestinal mucosa: not just trefoil peptides. World J Gastroenterol 2008; 14:3602-3603.
127. Karagiannides I, Pothoulakis C. Neuropeptides, mesenteric fat, and intestinal inflammation. Ann N Y Acad Sci 2008; 1144:127-135.
128. Koon HW, Zhao D, Xu H, et al. Substance P-mediated expression of the proangiogenic factor CCN1 modulates the course of colitis. Am J Pathol 2008; 173:400-410.
129. Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J Pharmacol 2008; 582:145-153.
130. Coates MD, Johnson AC,Greenwood-VanMeerveld B, MaweGM. Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil 2006; 18:464-471.
131. Costedio MM, Coates MD, Danielson AB, et al. Serotonin signaling in diverticular disease. J Gastrointest Surg 2008; 12:1439-1454.
132. Kushnir-Sukhov NM, Gilfillan AM, Coleman JW, et al. 5-hydroxytryptamine induces mast cell adhesion and migration. J Immunol 2006; 177:6422-6432.
133. Leon-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 2007; 109:3139-3146.
134. Nocito A, Dahm F, Jochum W, et al. Serotonin regulates macrophagemediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 2007; 68:5152-5158.
135. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007; 19 (Suppl 2):25-31.
136. Spiller R. Serotonin and GI clinical disorders. Neuropharmacology 2008; 55:1072-1080.
137. Stead RH. Innervation of mucosal immune cells in the gastrointestinal tract. Regul Immunol 2002; 4:91-99.
138. Idzko M, Panther E, Stratz C, et al. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunl 2004; 172:6011-6019.
139. Razani-Boroujerdi S. Role of muscarinic receptors in the regulation of immune and inflammatory responses. J Neuroimmunol 2008; 194:83-88.
140. Fiebich BL, Akundi RS, Seidel M, et al. Expression of 5-HT3A receptors in cells of the immune system. Scand J Rheumatol Suppl 2004; 119:9-11.
141. Vega Lde L, Muñoz E, Calzado MA, et al. The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem Pharmacol 2005; 70:369-380.
142. Yin J, Albert RH, Tretiakova AP, Jameson BA. 5-HT(1B) receptors play a prominent role in the proliferation of T-lymphocytes. J Neuroimmunol 2006; 181:68-81.
143. Yang JB. Expression of mRNA for multiple serotonin (5-HT) receptor types/subtypes by the peripheral blood mononuclear cells of rhesus macaques. J Neuroimmunol 2006; 178:24-29.
144. Young MR, Matthews JP. Serotonin regulation of T-cell subpopulations and of macrophage accessory function. Immunology 1995; 84:148-152.
145. Ganea D, Delgado M. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Arch Immunol Ther Exp (Warsz) 2001; 49:101-110.
146. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. Brain Behav Immun 2008; 22:35-41.
147. Kawashima K, Yoshikawa K, Fujii YX, et al. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci 2007; 80:2314-2319.
148. Wood JD. Enteric neuroimmunophysiology and pathophysiology. Gastroenterology 2004; 127:635-657.
149. Kraneveld AD, Rijnierse A, Nijkamp FP, Garssen J. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol 2008; 585:361-374.
150. Collins SM, Hurst SM, Main C, et al. Effect of inflammation of enteric nerves. Cytokine-induced changes in neurotransmitter content and release. Ann N Y Acad Sci 1992; 664:415-424.
151. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med 2008; 8:247-252.
152. Mawdsley JE, Jenkins DG, Macey MG, et al. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am J Gastroenterol 2008; 103:1460-1551.
153. Gad M, Pedersen AE, Kristensen NN, et al. Blockage of the neurokinin 1 receptor and capsaicin-induced ablation of the enteric afferent nerves protect SCID mice against T-cell-induced chronic colitis. Inflamm Bowel Dis 2009; 15:1174-1182.
154. Tache Y, Brunnhuber S. From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases. Ann N Y Acad Sci 2008; 1148:29-41.
155. Gravanis A, Margioris AN. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem 2005; 12:1503-1512.
156. Van Tol HH, Snijdewint FG, Boer GJ, Burbach JP. Postnatal development of vasopressin mRNA content in supraoptic and paraventricular nucleus of the Wistar rat. Neurosci Lett 1986; 6:1-6.
157. Grider Jr, Murthy KS, Jin JG, Makhlouf GM, et al. Stimulation of nitric oxide from muscle cells by VIP: prejunctional enhancement of VIP release. Am J Physiol 1992; 25:G774-G778.
158. Cooke HJ, Christofi F. Physiology of the gastrointestinal tract. 4th ed. Vol.1. Enteric neural regulation of mucosal secretion. New York: Elsevier: pp. 737-762.
159. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and IBS. Gastroenterology 2004; 126:1657-1664.